Swedbank AB Reduces Stock Position in Avantor, Inc. (NYSE:AVTR)

Swedbank AB decreased its holdings in Avantor, Inc. (NYSE:AVTR) by 10.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 93,887 shares of the company’s stock after selling 11,111 shares during the period. Swedbank AB’s holdings in Avantor were worth $1,978,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Forsta AP Fonden increased its holdings in Avantor by 3.3% during the fourth quarter. Forsta AP Fonden now owns 151,800 shares of the company’s stock valued at $3,198,000 after buying an additional 4,900 shares during the period. Robeco Institutional Asset Management B.V. increased its holdings in shares of Avantor by 38.1% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 119,063 shares of the company’s stock valued at $2,509,000 after acquiring an additional 32,838 shares during the period. CKW Financial Group raised its position in shares of Avantor by 116.7% in the 4th quarter. CKW Financial Group now owns 5,200 shares of the company’s stock worth $110,000 after acquiring an additional 2,800 shares in the last quarter. Pacer Advisors Inc. lifted its stake in shares of Avantor by 0.5% during the 4th quarter. Pacer Advisors Inc. now owns 99,825 shares of the company’s stock worth $2,103,000 after purchasing an additional 542 shares during the last quarter. Finally, Blue Trust Inc. boosted its position in Avantor by 6.9% during the fourth quarter. Blue Trust Inc. now owns 8,069 shares of the company’s stock valued at $170,000 after purchasing an additional 522 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Wells Fargo & Company reduced their target price on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating for the company in a report on Monday, October 28th. Raymond James reduced their price objective on shares of Avantor from $29.00 to $26.00 and set an “outperform” rating for the company in a research note on Tuesday, January 21st. Barclays lowered their target price on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a research note on Friday, October 25th. Robert W. Baird reduced their price target on Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a research report on Monday, October 28th. Finally, UBS Group reissued a “neutral” rating and issued a $25.00 price objective (down previously from $29.00) on shares of Avantor in a research report on Friday, January 17th. Three research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $27.38.

Avantor Stock Performance

Shares of NYSE AVTR opened at $22.26 on Monday. The company has a 50 day simple moving average of $21.69 and a two-hundred day simple moving average of $23.45. The stock has a market cap of $15.15 billion, a price-to-earnings ratio of 48.38, a PEG ratio of 3.82 and a beta of 1.28. The company has a current ratio of 1.54, a quick ratio of 1.06 and a debt-to-equity ratio of 0.84. Avantor, Inc. has a 12 month low of $19.59 and a 12 month high of $28.00.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.